SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 135.53 |
| Enterprise Value ($M) | -244.96 |
| Book Value ($M) | 407.98 |
| Book Value / Share | 5.75 |
| Price / Book | 0.33 |
| NCAV ($M) | 287.26 |
| NCAV / Share | 4.05 |
| Price / NCAV | 0.47 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.22 |
| Return on Assets (ROA) | -0.19 |
| Return on Equity (ROE) | -0.23 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 29.37 |
| Current Ratio | 29.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 380.49 |
| Assets | 501.20 |
| Liabilities | 93.23 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -128.19 |
| Net Income | -108.79 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -99.70 |
| Cash from Investing | -129.56 |
| Cash from Financing | 226.08 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Commodore Capital Lp | 0.50 | -92.45 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 0.00 | -100.00 | |
| 13D/A | LSP 6 Holding C.V. | 4.00 | 0.00 | |
| 13G | Tang Capital Management Llc | 9.90 | ||
| 13G | Citadel Advisors Llc | 5.40 | ||
| 13G/A | Flynn James E | 3.05 | -36.62 | |
| 13G/A | Adage Capital Management, L.P. | 5.10 | ||
| 13G | BlackRock, Inc. | 6.00 | 0.00 | |
| 13G/A | Boxer Capital Management, LLC | 4.90 | ||
| 13D/A | Samsara BioCapital, L.P. | 5.40 | 31.38 | |
| 13D/A | Ra Capital Management, L.p. | 18.90 | 76.81 | |
| 13D/A | Glaxosmithkline Plc | 4.50 | 0.00 | |
| 13D/A | New Enterprise Associates 15, L.P. | 5.10 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 428,668 | 1,047,635 | 40.92 | |
| 566,204 | 1,504,204 | 37.64 | |
| 309,803 | 1,128,162 | 27.46 | |
| 447,011 | 1,600,112 | 27.94 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MYGN – Myriad Genetics, Inc. | NBIX – Neurocrine Biosciences, Inc. |
| NEOG – Neogen Corporation | NMRA – Neumora Therapeutics, Inc. |
| NUVL – Nuvalent, Inc. |
Financial data and stock pages provided by
Fintel.io